

Annette E Hay, Mb Chb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9374758/publications.pdf>

Version: 2024-02-01

48
papers

1,811
citations

840776

11
h-index

289244

40
g-index

48
all docs

48
docs citations

48
times ranked

2761
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1422-1428.	6.3	1
2	Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. <i>Current Oncology</i> , 2021, 28, 1256-1261.	2.2	2
3	A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data. <i>Current Oncology</i> , 2021, 28, 1153-1160.	2.2	3
4	Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN003/MYX.1 single arm phase II trial. <i>American Journal of Hematology</i> , 2021, 96, 552-560.	4.1	11
5	Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. <i>Clinical Trials</i> , 2021, 18, 500-504.	1.6	2
6	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. <i>Current Oncology</i> , 2021, 28, 1518-1527.	2.2	1
7	A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 333-342.	2.2	0
8	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 766-774.	0.4	4
9	Validation, Implementation, and Clinical Impact of the OncoPrint Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1292-1305.	2.8	8
10	The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. <i>Current Oncology</i> , 2021, 28, 3649-3658.	2.2	0
11	Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial. <i>Blood</i> , 2021, 138, 4076-4076.	1.4	0
12	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. <i>Blood Advances</i> , 2020, 4, 2011-2017.	5.2	12
13	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1653-1659.	1.3	6
14	Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e791-e800.	0.4	10
15	Risk Factors for the Development of Skin Cancers in Patients with Chronic Lymphocytic Leukemia: A Retrospective Cohort Study. <i>Blood</i> , 2020, 136, 15-16.	1.4	2
16	CAR T-cells: costs, comparisons, and commentary. <i>Journal of Medical Economics</i> , 2019, 22, 613-615.	2.1	42
17	Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?. <i>Journal of Oncology Practice</i> , 2019, 15, e807-e824.	2.5	10
18	Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e272-e273.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes. <i>Clinical Trials</i> , 2019, 16, 14-17.	1.6	6
20	A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 912-919.	1.3	18
21	Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1871-1871.	1.4	3
22	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial. <i>Blood</i> , 2019, 134, 3905-3905.	1.4	7
23	Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral. <i>Blood</i> , 2019, 134, 768-768.	1.4	2
24	Diagnosing Absolute Iron-Deficiency Anemia in Patients on Hemodialysis in a Tertiary Care Centre: A Retrospective Chart Review. <i>Blood</i> , 2019, 134, 4814-4814.	1.4	1
25	Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials. <i>International Journal of Cardiology</i> , 2018, 262, 110-116.	1.7	13
26	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E49-E52.	4.1	14
27	MCRN 003/MYX 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies. <i>Blood</i> , 2018, 132, 1984-1984.	1.4	1
28	Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy – Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial. <i>Blood</i> , 2018, 132, 2980-2980.	1.4	0
29	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. <i>Leukemia and Lymphoma</i> , 2017, 58, 64-69.	1.3	11
30	Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2319-2327.	1.3	23
31	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	1.4	1,084
32	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 1358-1365.	1.3	35
33	Linkage of Clinical Trial and Administrative Data: A Survey of Cancer Patient Preferences. <i>Current Oncology</i> , 2017, 24, 161-167.	2.2	16
34	A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. <i>Leukemia and Lymphoma</i> , 2016, 57, 1463-1466.	1.3	26
35	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. <i>Blood</i> , 2016, 128, 4526-4526.	1.4	17
36	Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. <i>Blood</i> , 2016, 128, 690-690.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. Journal of the National Cancer Institute, 2015, 107, .	6.3	20
38	A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiDÂ® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2015, 126, 2960-2960.	1.4	0
39	Testing for Heparin Induced Thrombocytopenia: Comparison of Practice at an Academic Center with Choosing Wisely Guidelines. Blood, 2015, 126, 3469-3469.	1.4	0
40	Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology, 2014, 32, 3490-3496.	1.6	358
41	Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12. Blood, 2014, 124, 1712-1712.	1.4	5
42	A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193. Blood, 2014, 124, 5670-5670.	1.4	3
43	A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapsed or Refractory Multiple Myeloma; NCIC Clinical Trials Group IND.191. Blood, 2014, 124, 5734-5734.	1.4	0
44	A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12. Blood, 2013, 122, 155-155.	1.4	7
45	Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness. Journal of Clinical Oncology, 2012, 30, 3155-3157.	1.6	9
46	Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood, 2012, 120, 548-548.	1.4	4
47	Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. Blood, 2012, 120, 745-745.	1.4	4
48	Latency of onset of de novo myelodysplastic syndromes. Haematologica, 2004, 89, 1392-4.	3.5	4